As per the agreed terms, Temasek will purchase $35m of the notes in an initial tranche and, remaining $25m in a second tranche.
Commenting on the transaction, Amyris president & CEO John Melo said that this funding will provide with financial flexibility that will enable the company to achieve its business objectives.
"Our progress to date developing and manufacturing molecules developed under our proprietary synthetic biology platform, including ramp up of our new industrial fermentation facility for the production of farnesene in Brazil, continues to demonstrate our leadership in the sector," added Melo.
Amyris engages in the provision of various alternatives to a range of petroleum-sourced products for the specialty chemical and transportation fuel markets across the world.
The company has a strategic partnership with Total for the development of renewable diesel and jet fuels.
